These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

957 related articles for article (PubMed ID: 30132104)

  • 1.
    Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
    Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective comparison of
    Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
    Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
    Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Comparison of
    Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
    J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Nikitas J; Gafita A; Benz MR; Djaïleb L; Farolfi A; Hotta M; Sonni I; Alano R; Rettig M; Shen J; Armstrong W; Grogan T; Liu S; Czernin J; Calais J
    Sci Rep; 2024 Oct; 14(1):24411. PubMed ID: 39420060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.
    Domachevsky L; Bernstine H; Goldberg N; Nidam M; Catalano OA; Groshar D
    Eur Radiol; 2020 Jan; 30(1):328-336. PubMed ID: 31332559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
    Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
    Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study Comparing
    Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-Head Comparison of
    Schilham MGM; Zamecnik P; Privé BM; Israël B; Rijpkema M; Scheenen T; Barentsz JO; Nagarajah J; Gotthardt M
    J Nucl Med; 2021 Sep; 62(9):1258-1263. PubMed ID: 33517328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective comparison of whole-body MRI and
    Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrid Ga-68 prostate-specific membrane antigen PET/MRI in the detection of skeletal metastasis in patients with newly diagnosed prostate cancer: Contribution of each part to the diagnostic performance.
    Asa S; Ozgur E; Uslu-Besli L; Ince B; Sager S; Demirdag C; Guner E; Sayman HB; Bakir B; Sonmezoglu K
    Nucl Med Commun; 2023 Jan; 44(1):65-73. PubMed ID: 36378618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
    Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
    Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observer Agreement and Accuracy of
    Zacho HD; Fonager RF; Nielsen JB; Haarmark C; Hendel HW; Johansen MB; Mortensen JC; Petersen LJ
    J Nucl Med; 2020 Mar; 61(3):344-349. PubMed ID: 31481577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.